Skip to content
MarketScale
‹ Back to IndustriesSciences

Japan’s Radioactive Water Release Won’t Impact Neighboring Countries, Despite China’s Opposition and Ban on Japanese Seafood

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Alexandra Simon · ChinaFukushimaJapanRadioactive Release
Share

Key takeaways

01

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima.

02

However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive…

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

With news of China banning seafood from Japan, the debate around nuclear energy has always been fraught with concerns about safety, especially following high-profile incidents like Fukushima. However, it’s worth noting that nuclear plants across the world, including officials in countries vocally concerned about Japan’s handling of tritiated water, routinely have their own radioactive waste responsibilities. 

It’s easy to get caught in the emotion and politics of the situation, especially when it involves terms like “radioactive release,” but understanding the science and safety protocols is crucial. Independent organizations like the International Atomic Energy Agency (IAEA) provide not just oversight but also expertise in making sure that any release is carried out to stringent safety standards. For instance, the tritium levels being released from Fukushima meet standards set by the World Health Organization and the Japanese government. The release of tritiated water is a monitored, understood, and internationally sanctioned activity that comes as a part of the territory with nuclear energy. 

To further explain the safety of this effort and how public perception impacts nuclear outlook is Ken Petersen, President of the American Nuclear Society. He brings years of experience and knowledge on the subject. Previously he was the vice president for nuclear fuels at Exelon Generation Company (EGC) for more than 12 years. He even worked on a contract with the U.S. Department of Energy, and has a Bachelor’s and Master’s in nuclear engineering from the University of Wisconsin.

Petersen mentioned that Japan’s release of tritiated water — water that’s been heavily treated, undergoes safety protocols set by global standards. He further added that China’s opposition bears hypocrisy given that they, too, have also released radioactive water under those same guidelines.

Petersen’s Thoughts on Radioactive Water Release

“Sure. So, I mean, the site is no longer has room for expanded storage. So, something has to happen with the tritiated water. It’s been, you know, filtered twice and, you know, what is remaining is a little bit of tritium that’s going to be blended down even further and released. So, it’s going to be monitored and released. The IAEA has reviewed it. They will have somebody there monitoring it to assure that everything is done appropriately. So, this is no different than any other plant. 

“So, when you have a radioactive release, it is monitored and it meets the criteria. And it’s, you know, one-seventh of the World Health Organization levels. And it’s a fortieth of what the Japanese government limits are. So, it’s a very understood and very small amount. Well, there’s a history from their neighbors where, you know, some of their neighbors don’t get along very well. But the neighbors who are speaking loudly also have reactors where they’ll do the exact same thing. You know, they will have tritium releases. They will be monitored and be well within safety levels. Yeah, this shouldn’t impact that at all. So, this is a very unfortunate situation, you know, that the Fukushima plants had the earthquake and following tsunami. And it resulted with this large storage of tritiated water and it is just a monitored release. It should have no impact on the outlook for new nuclear.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

AS
Alexandra SimonFreelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne’s AI agents push materials R&D toward days-long cycles

Argonne National Laboratory is utilizing AI agents to accelerate materials R&D cycles, reducing the time span to just a few days. This advancement hinges on prioritizing dataflow and security over larger AI models. The novel approach aims to streamline processes and enhance the efficiency of research and development activities.

  • 01Argonne National Laboratory is using AI agents to significantly shorten materials R&D cycles.
  • 02The focus of procurement has shifted to dataflow and security rather than larger AI models.
  • 03Improved workflows facilitate more efficient research and development efforts.

Aug 25, 2026

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

Cancer diagnostics growth is forcing labs to budget for data, not just instruments

The growth in cancer diagnostics is prompting laboratories to allocate budgets not only for instruments but also for data management. Market forecasts predict an increase in the cancer diagnostics market from $29.86 billion in 2026 to $44.92 billion by 2031. Staffing is identified as a significant operational constraint according to industry insights.

  • 01Cancer diagnostics market is expected to grow from $29.86 billion in 2026 to $44.92 billion by 2031.
  • 02Laboratories are increasingly required to budget for data management alongside instruments.
  • 03Staffing is a major operational constraint in the growth of cancer diagnostics.

Aug 24, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Alexandra Simon

Freelance Writer

Alexandra is a freelance writer based in New York City. She's a big fan of true crime television and the Oxford comma. She has a background in local news reporting, beat reporting, magazine writing, SEO writing, and copywriting.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512